VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH MM 2018 | Combining bortezomib and lenalidomide-based regimens for frontline MM

Frontline transplant-ineligible multiple myeloma (MM) is typically treated with VMP (bortezomib, melphalan, prednisolone) or Rd (lenalidomide, dexamethasone) based regimens. However, efforts have recently been made to combine these treatments, as discussed here by Kwee Yong, PhD, FRCP, FRCPath, from University College London, London, UK. Prof. Yong highlights the RVd (lenalidomide, bortezomib, dexamethasone) lite treatment protocol, as well as alternating or sequential regimens.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter